• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P-糖蛋白调节剂环孢素A对大鼠体内伊立替康及其代谢产物SN-38经胃肠道排泄的影响。

Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

作者信息

Arimori Kazuhiko, Kuroki Noriaki, Hidaka Muneaki, Iwakiri Tomomi, Yamsaki Keishi, Okumura Manabu, Ono Hiroshige, Takamura Norito, Kikuchi Masahiko, Nakano Masahiro

机构信息

Department of Pharmacy, Miyazaki Medical College, 5200 Kihara, Kiyotake-cho, Miyazaki-gun, Miyazaki 889-1692, Japan.

出版信息

Pharm Res. 2003 Jun;20(6):910-7. doi: 10.1023/a:1023847521767.

DOI:10.1023/a:1023847521767
PMID:12817897
Abstract

PURPOSE

The purpose of this work was to investigate the role of the hepatic and intestinal P-glycoprotein (P-gp) and canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2 (cMOAT/MRP2) on both biliary excretion and intestinal exsorption of irinotecan hydrochloride (CPT-11) and its metabolite, SN-38, in the lactone and carboxylate forms. Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.

METHODS

The transcellular transport of CPT-11 and SN-38 was examined by using LLC-PK1 derivative cell lines transfected with murine mdrla both in the absence or in the presence of CsA. The excretions of the compounds through the biliary and intestinal membrane routes were investigated by in situ perfusion technique.

RESULTS

Basolateral-to-apical transport of CPT-11 lactone in L-mdr1a cells was significantly decreased by CsA (10 microM). The transcellular transport of SN-38 lactone showed similar behaviors as those of CPT-11 lactone. The biliary excretion and the intestinal exsorption of both forms of CPT-11 and SN-38 were significantly inhibited when the drug was co-administered with CsA.

CONCLUSIONS

The transports of CPT-11 and SN-38 via the biliary route seem to be essentially related with cMOAT/MRP2, whereas those of both compounds via the intestinal membrane seem to be related with P-gp.

摘要

目的

本研究旨在探讨肝脏和肠道中的P-糖蛋白(P-gp)以及胆小管多特异性有机阴离子转运体/多药耐药相关蛋白2(cMOAT/MRP2)在盐酸伊立替康(CPT-11)及其代谢产物SN-38内酯型和羧酸盐型的胆汁排泄及肠道重吸收中的作用。使用环孢素A(CsA)调节P-gp和cMOAT/MRP2。

方法

利用转染了小鼠mdrla的LLC-PK1衍生细胞系,在不存在或存在CsA的情况下检测CPT-11和SN-38的跨细胞转运。通过原位灌注技术研究化合物经胆汁和肠膜途径的排泄情况。

结果

CsA(10微摩尔)显著降低了L-mdr1a细胞中CPT-11内酯从基底外侧到顶端的转运。SN-38内酯的跨细胞转运表现出与CPT-11内酯相似的行为。当药物与CsA共同给药时,CPT-11和SN-38两种形式的胆汁排泄和肠道重吸收均受到显著抑制。

结论

CPT-11和SN-38经胆汁途径的转运似乎主要与cMOAT/MRP2有关,而这两种化合物经肠膜的转运似乎与P-gp有关。

相似文献

1
Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.P-糖蛋白调节剂环孢素A对大鼠体内伊立替康及其代谢产物SN-38经胃肠道排泄的影响。
Pharm Res. 2003 Jun;20(6):910-7. doi: 10.1023/a:1023847521767.
2
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.喜树碱衍生物伊立替康(CPT-11)、其代谢产物SN-38及其葡糖醛酸苷的胆汁排泄机制多样性:胆小管多特异性有机阴离子转运体和P-糖蛋白的作用
Cancer Chemother Pharmacol. 1998;42 Suppl:S44-9. doi: 10.1007/s002800051078.
3
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.伊立替康(CPT-11)及其代谢产物经人肠道Caco-2细胞的主动跨上皮转运
Anticancer Drugs. 2001 Jun;12(5):419-32. doi: 10.1097/00001813-200106000-00003.
4
Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.多特异性有机阴离子转运体负责喜树碱衍生物伊立替康及其代谢产物在大鼠体内的胆汁排泄。
J Pharmacol Exp Ther. 1997 Apr;281(1):304-14.
5
Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Cancer Res. 1997 May 15;57(10):1934-8.
6
Biliary excretion of irinotecan and its metabolites.伊立替康及其代谢产物的胆汁排泄。
J Pharm Pharm Sci. 2004 Jan 23;7(1):13-8.
7
Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.伊立替康内酯和羧酸盐形式在啮齿动物胃肠道中的排泄及其药效学
Pharm Res. 2001 Jun;18(6):814-22. doi: 10.1023/a:1011040529881.
8
Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.橙皮苷通过调节大鼠肝脏Mrp2对CPT-11及其活性代谢产物SN-38药代动力学的影响。
Biopharm Drug Dispos. 2016 Oct;37(7):421-432. doi: 10.1002/bdd.2024. Epub 2016 Sep 15.
9
Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.伊立替康在过表达外排转运蛋白Pgp、cMOAT和MRP1的Caco-2细胞和MDCK II细胞中的肠道转运。
Drug Metab Dispos. 2002 Jul;30(7):763-70. doi: 10.1124/dmd.30.7.763.
10
Pharmacogenetics of irinotecan metabolism and transport: an update.伊立替康代谢与转运的药物遗传学:最新进展
Toxicol In Vitro. 2006 Mar;20(2):163-75. doi: 10.1016/j.tiv.2005.06.045. Epub 2005 Nov 3.

引用本文的文献

1
Saikosaponin-d Attenuates Irinotecan-Induced Intestinal Toxicity via TAK1/NF-κB Pathway and Enhances Antitumor Efficacy.柴胡皂苷d通过TAK1/NF-κB途径减轻伊立替康诱导的肠道毒性并增强抗肿瘤疗效。
J Inflamm Res. 2025 Jun 18;18:7973-7988. doi: 10.2147/JIR.S504696. eCollection 2025.
2
Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection.人脑脊液中拓扑替康分析的高效液相色谱法的建立与验证及其在脑室内注射后拓扑替康消除评价中的应用
Cancers (Basel). 2021 Sep 16;13(18):4643. doi: 10.3390/cancers13184643.
3

本文引用的文献

1
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.多药耐药相关蛋白2(ABCC2)与多种治疗药物之间相互作用的可能性:丙磺舒作为伊立替康代谢物胆汁排泄的候选抑制剂。
Drug Metab Pharmacokinet. 2002;17(1):23-33. doi: 10.2133/dmpk.17.23.
2
Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition.多药耐药相关蛋白2(MRP2)的表达调控及其在药物处置中的作用。
J Pharmacol Exp Ther. 2002 Aug;302(2):407-15. doi: 10.1124/jpet.102.035014.
3
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Digoxin absorption decreased independently of P-gp activity in rats with irinotecan-induced gastrointestinal damage.
在伊立替康诱导的胃肠道损伤大鼠中,地高辛吸收减少,且与P-糖蛋白活性无关。
J Pharm Health Care Sci. 2021 Jul 1;7(1):24. doi: 10.1186/s40780-021-00207-w.
4
Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.西罗莫司的药代动力学变异性表明治疗药物监测在儿科肿瘤学中的相关性。
Pharmaceutics. 2021 Mar 30;13(4):470. doi: 10.3390/pharmaceutics13040470.
5
Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.生姜泻心汤通过调节代谢酶和转运体改变伊立替康的药代动力学:一种减轻胃肠道毒性的多靶点疗法
Front Pharmacol. 2017 Oct 27;8:769. doi: 10.3389/fphar.2017.00769. eCollection 2017.
6
Mechanism of modulation through PI3K-AKT pathway about Nepeta cataria L.'s extract in non-small cell lung cancer.荆芥提取物通过PI3K-AKT途径对非小细胞肺癌的调控机制
Oncotarget. 2017 May 9;8(19):31395-31405. doi: 10.18632/oncotarget.15608.
7
FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.新型喜树碱类似物FL118在人肿瘤异种移植模型中克服了伊立替康和拓扑替康耐药性。
Am J Transl Res. 2015 Oct 15;7(10):1765-81. eCollection 2015.
8
Liquid Chromatographic Method for Irinotecan Estimation: Screening of P-gp Modulators.用于伊立替康定量的液相色谱法:P-糖蛋白调节剂的筛选
Indian J Pharm Sci. 2015 Jan-Feb;77(1):14-23. doi: 10.4103/0250-474x.151577.
9
Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.新型二肽基肽酶-4抑制剂阿格列汀在大鼠和犬体内的药代动力学特征
Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):87-96. doi: 10.1007/s13318-013-0119-z. Epub 2013 Feb 23.
10
Functional characterization of liver enhancers that regulate drug-associated transporters.肝脏增强子的功能特征分析及其对药物相关转运体的调控作用。
Clin Pharmacol Ther. 2011 Apr;89(4):571-8. doi: 10.1038/clpt.2010.353. Epub 2011 Mar 2.
伊立替康(CPT-11)的临床药代动力学与代谢
Clin Cancer Res. 2001 Aug;7(8):2182-94.
4
Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.伊立替康内酯和羧酸盐形式在啮齿动物胃肠道中的排泄及其药效学
Pharm Res. 2001 Jun;18(6):814-22. doi: 10.1023/a:1011040529881.
5
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.伊立替康(CPT-11)及其代谢产物经人肠道Caco-2细胞的主动跨上皮转运
Anticancer Drugs. 2001 Jun;12(5):419-32. doi: 10.1097/00001813-200106000-00003.
6
pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Int J Cancer. 1999 Nov 12;83(4):491-6. doi: 10.1002/(sici)1097-0215(19991112)83:4<491::aid-ijc10>3.0.co;2-m.
7
Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.P-糖蛋白可能参与大鼠体内CPT-11的胆汁排泄。
Drug Metab Dispos. 1999 Apr;27(4):440-1.
8
Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.CPT-11及其代谢产物在人KB衍生细胞系中的主动外排。
J Pharmacol Exp Ther. 1999 Feb;288(2):735-41.
9
Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.CPT-11及其代谢产物在人体内的胆汁排泄机制:原发性主动转运体的参与
Cancer Res. 1998 Nov 15;58(22):5137-43.
10
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.喜树碱衍生物伊立替康(CPT-11)、其代谢产物SN-38及其葡糖醛酸苷的胆汁排泄机制多样性:胆小管多特异性有机阴离子转运体和P-糖蛋白的作用
Cancer Chemother Pharmacol. 1998;42 Suppl:S44-9. doi: 10.1007/s002800051078.